Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.

Irenaeus SMM, Nielsen D, Ellmark P, Yachnin J, Deronic A, Nilsson A, Norlén P, Veitonmäki N, Wennersten CS, Ullenhag GJ.

Int J Cancer. 2019 Sep 1;145(5):1189-1199. doi: 10.1002/ijc.32141. Epub 2019 Mar 8.

PMID:
30664811
2.

Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.

Boman K, Andersson G, Wennersten C, Nodin B, Ahlgren G, Jirström K.

Biomark Res. 2017 Mar 14;5:10. doi: 10.1186/s40364-017-0090-y. eCollection 2017.

3.

Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study.

Andersson G, Wennersten C, Borgquist S, Jirström K.

Biol Sex Differ. 2016 Dec 9;7:66. eCollection 2016.

4.

Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.

Wennersten C, Andersson G, Boman K, Nodin B, Gaber A, Jirström K.

Diagn Pathol. 2014 Oct 3;9:189. doi: 10.1186/s13000-014-0189-5.

5.

Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.

Andersson G, Wennersten C, Gaber A, Boman K, Nodin B, Uhlén M, Segersten U, Malmström PU, Jirström K.

BMC Urol. 2014 May 12;14:36. doi: 10.1186/1471-2490-14-36.

6.

Towards squalamine mimics: synthesis and antibacterial activities of head-to-tail dimeric sterol-polyamine conjugates.

Chen WH, Wennersten C, Moellering RC Jr, Regen SL.

Chem Biodivers. 2013 Mar;10(3):385-93. doi: 10.1002/cbdv.201100431.

PMID:
23495155
7.

Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Joukhadar C, Pillai S, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2010 Feb;54(2):773-7. doi: 10.1128/AAC.00348-09. Epub 2009 Nov 23.

8.

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW.

Clin Infect Dis. 2009 Oct 15;49(8):1169-74. doi: 10.1086/605636.

PMID:
19769538
9.

Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus.

Tsakris A, Pillai SK, Gold HS, Thauvin-Eliopoulos C, Venkataraman L, Wennersten C, Moellering RC Jr, Eliopoulos GM.

J Antimicrob Chemother. 2007 Sep;60(3):649-51. Epub 2007 Jul 10.

PMID:
17623697
10.

Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2007 Jun;51(6):2223-5. Epub 2007 Apr 2.

11.

A bioconjugate approach toward squalamine mimics: Insight into the mechanism of biological action.

Chen WH, Shao XB, Moellering R, Wennersten C, Regen SL.

Bioconjug Chem. 2006 Nov-Dec;17(6):1582-91.

PMID:
17105239
12.

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK.

J Clin Microbiol. 2006 Feb;44(2):595-7.

13.

In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.

Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2005 Jul;49(7):3034-9.

14.

Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr, Gold HS.

J Infect Dis. 2004 Jul 15;190(2):311-7. Epub 2004 Jun 9.

PMID:
15216466
15.

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS.

J Infect Dis. 2003 Mar 15;187(6):929-38. Epub 2003 Mar 6.

PMID:
12660939
16.

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.

Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC Jr, Ferraro MJ, Gold HS.

J Infect Dis. 2002 Dec 1;186(11):1603-7. Epub 2002 Nov 4.

PMID:
12447736
17.

In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2002 Oct;46(10):3273-5.

18.

Prevalence of the fsr locus in Enterococcus faecalis infections.

Pillai SK, Sakoulas G, Gold HS, Wennersten C, Eliopoulos GM, Moellering RC Jr, Inouye RT.

J Clin Microbiol. 2002 Jul;40(7):2651-2.

19.

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Sakoulas G, Eliopoulos GM, Moellering RC Jr, Wennersten C, Venkataraman L, Novick RP, Gold HS.

Antimicrob Agents Chemother. 2002 May;46(5):1492-502.

20.
21.

Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ.

Lancet. 2001 Jul 21;358(9277):207-8.

PMID:
11476839
22.

Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer.

Torres Viera C, Tsiodras S, Gold HS, Coakley EP, Wennersten C, Eliopoulos GM, Moellering RC Jr, Inouye RT.

Antimicrob Agents Chemother. 2001 Mar;45(3):973-5.

23.

Diversity of domain V of 23S rRNA gene sequence in different Enterococcus species.

Tsiodras S, Gold HS, Coakley EP, Wennersten C, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2000 Nov;38(11):3991-3.

24.

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Boucher HW, Wennersten CB, Eliopoulos GM.

Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9.

25.

Activities of taurolidine in vitro and in experimental enterococcal endocarditis.

Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, Sofia RD, Eliopoulos GM.

Antimicrob Agents Chemother. 2000 Jun;44(6):1720-4.

26.

In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria.

Schülin T, Wennersten CB, Moellering RC Jr, Eliopoulos GM.

J Antimicrob Chemother. 1998 Sep;42(3):297-301.

PMID:
9786468
27.

Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Schülin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1998 Jun;42(6):1520-3.

28.

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

Souli M, Wennersten CB, Eliopoulos GM.

Int J Antimicrob Agents. 1998 Apr;10(1):23-30.

PMID:
9624540
29.

Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Eliopoulos GM, Wennersten CB, Gold HS, Schülin T, Souli M, Farris MG, Cerwinka S, Nadler HL, Dowzicky M, Talbot GH, Moellering RC Jr.

Antimicrob Agents Chemother. 1998 May;42(5):1088-92.

30.
32.

In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.

Schülin T, Wennersten CB, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1997 May;41(5):1196-202.

33.

In vitro activities in new oxazolidinone antimicrobial agents against enterococci.

Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr.

Antimicrob Agents Chemother. 1996 Jul;40(7):1745-7.

34.

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria.

Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Diagn Microbiol Infect Dis. 1996 May;25(1):35-41.

PMID:
8831043
35.

In vitro activity of WY-49605, a penem antimicrobial.

Eliopoulos GM, Wennersten CB, Cole G, Moellering RC Jr.

Int J Antimicrob Agents. 1995 Jul;5(4):251-7.

PMID:
18611676
36.

In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent.

Eliopoulos GM, Wennersten CB, Cole G, Chu D, Pizzuti D, Moellering RC Jr.

Antimicrob Agents Chemother. 1995 Apr;39(4):850-3.

37.

In vitro activities of two glycylcyclines against gram-positive bacteria.

Eliopoulos GM, Wennersten CB, Cole G, Moellering RC.

Antimicrob Agents Chemother. 1994 Mar;38(3):534-41.

38.

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.

Collins LA, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1994 Jan;38(1):144-6.

39.

In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

Malanoski GJ, Collins L, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 1993 Sep;37(9):2009-16.

40.

A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci.

Gold HS, Unal S, Cercenado E, Thauvin-Eliopoulos C, Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 1993 Aug;37(8):1604-9.

41.

In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr.

Antimicrob Agents Chemother. 1993 Jun;37(6):1364-6.

42.

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr.

Antimicrob Agents Chemother. 1993 Mar;37(3):598-601.

43.

Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin.

Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 1992 Nov;36(11):2526-8.

44.

Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci.

Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 1992 Oct;36(10):2201-3.

45.

Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens.

Hodges TL, Zighelboim-Daum S, Eliopoulos GM, Wennersten C, Moellering RC Jr.

Antimicrob Agents Chemother. 1992 Jan;36(1):121-5.

46.

Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution.

Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering RC Jr.

Antimicrob Agents Chemother. 1991 Nov;35(11):2180-4.

47.

Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance.

Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, Klimm K, Sapico FL, Bayer AS, Moellering RC Jr.

Antimicrob Agents Chemother. 1991 Jul;35(7):1408-12.

49.

Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis.

Rice LB, Eliopoulos GM, Wennersten C, Goldmann D, Jacoby GA, Moellering RC Jr.

Antimicrob Agents Chemother. 1991 Feb;35(2):272-6.

50.

Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward.

Rhinehart E, Smith NE, Wennersten C, Gorss E, Freeman J, Eliopoulos GM, Moellering RC Jr, Goldmann DA.

N Engl J Med. 1990 Dec 27;323(26):1814-8. No abstract available.

Supplemental Content

Loading ...
Support Center